deltatrials
Completed PHASE3 INTERVENTIONAL NCT00007189

Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

Sponsor: Johns Hopkins University

Conditions Alzheimer Disease
Interventions Celecoxib (Celebrex) Naproxen Sodium (Aleve)
Updated 5 times since 2017 Last updated: Oct 18, 2016 Started: Jan 31, 2001 Primary completion: May 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alzheimer Disease, this trial is completed. The trial is conducted by Johns Hopkins University and has accumulated 5 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Johns Hopkins University
  • National Institute on Aging (NIA)
  • Seattle Institute for Biomedical and Clinical Research
  • University of Washington
  • VA Puget Sound Health Care System
Data source: Seattle Institute for Biomedical and Clinical Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations